Hematopoietic stem cell transplantation for primary immunodeficiency diseases

Area of Science:

• Immunology
• Hematology
• Transplantation Medicine

Background:

• Primary immunodeficiencies (PIDs) are a group of genetic disorders affecting the immune system.
• Hematopoietic stem cell transplantation (HSCT) has emerged as a potentially curative treatment for various PIDs.
• Significant advancements have improved the success rates and safety of HSCT.

Purpose of the Study:

• To highlight the increasing success and expanding applications of HSCT in treating PIDs.
• To discuss the key factors contributing to improved HSCT outcomes.
• To emphasize the importance of precise diagnosis and pre-transplant assessment for optimal results.

Main Methods:

• Review of current HSCT protocols and outcomes for PIDs.
• Analysis of factors influencing HSCT success, including donor matching and supportive care.
• Discussion of diagnostic and prognostic assessments prior to HSCT.

Main Results:

• HSCT achieves up to 90% cure rates for severe combined immunodeficiency (SCID).
• 70-80% cure rates are observed for other PIDs with matched unrelated donors, reaching 95% in young patients with specific conditions like Wiskott-Aldrich syndrome.
• HSCT is recognized as the optimal treatment for chronic granulomatous disease (CGD) and can cure CD40 ligand deficiency and immune dysregulation disorders.

Conclusions:

• HSCT is a highly successful and increasingly utilized therapy for a broad spectrum of PIDs.
• Improvements in tissue typing, supportive care, and prophylaxis have dramatically enhanced HSCT efficacy.
• Precise molecular diagnostics and thorough pre-HSCT evaluations are crucial for maximizing patient benefit and outcomes.